# Quo Vadis translational neuroscience?

**Authors:** Ekrem Dere

PMC · DOI: 10.1515/tnsci-2025-0393 · Translational Neuroscience · 2026-02-26

## TL;DR

This review explores how neuroscience research can be translated into clinical applications for brain diseases.

## Contribution

The paper provides a comprehensive overview of recent developments and challenges in translational neuroscience.

## Key findings

- Recent advancements in diagnostic innovation and therapeutic translation are highlighted.
- Integrative modeling is identified as a key area for future research.
- The paper discusses urgent challenges and proposes viable solutions for the field.

## Abstract

Translational neuroscience is a research discipline that aims to transfer findings from basic research in neuroscience into clinical applications. The main goal of this research discipline is to gain molecular and mechanistic insight into brain diseases and to devise novel diagnostic tools and therapeutic applications. This review is organized in three major sections which address recent developments in diagnostic innovation, therapeutic translation and integrative modelling. Furthermore, the most urgent problems and challenges of translational neuroscience as a research discipline are presented and viable solutions are discussed. Promising novel methods are presented, and suggestions for new research approaches are made. Although translational neuroscience deals with diseases of the most complex human organ that there is, the brain, it is likely to turn out to be one of the few disciplines in life sciences that will continue to see steady progress and discoveries.

## Full-text entities

- **Genes:** Psen1 (presenilin 1) [NCBI Gene 19164] {aka Ad3h, PS-1, PS1, S182}, TF (transferrin) [NCBI Gene 7018] {aka HEL-S-71p, PRO1557, PRO2086, TFQTL1}
- **Diseases:** schizophrenia (MESH:D012559), CNS-related diseases (MESH:D002493), tumor (MESH:D009369), neurotoxicity (MESH:D020258), Alzheimer's (MESH:D000544), Mental disorders (MESH:D001523), Parkinson's (MESH:D010300), inflammatory (MESH:D007249), neurodegenerative diseases (MESH:D019636), psychopathological disease (MESH:D004194), neurological (MESH:D009461), major depression (MESH:D003865), learning and memory deficits (MESH:D007859), neurological and neuropsychiatric diseases (MESH:D020271), toxicity (MESH:D064420), psychotic disorders (MESH:D011618), brain inflammation (MESH:D004660), delusions (MESH:D063726), brain injury (MESH:D001930), brain disease (MESH:D001927), disorders of consciousness (MESH:D003244), nervous system injury or degeneration (MESH:D020196), hallucinations (MESH:D006212), coma (MESH:D003128), amyloid (MESH:C000718787), bipolar disorder (MESH:D001714), neuronal loss (MESH:D009410)
- **Chemicals:** polyethylene glycol (MESH:D011092), clozapine (MESH:D003024), 5xFAD (-), naringenin (MESH:C005273), lipid (MESH:D008055)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** V717I, L286V, I716V, M146L

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12949644/full.md

## References

170 references — full list in the complete paper: https://tomesphere.com/paper/PMC12949644/full.md

---
Source: https://tomesphere.com/paper/PMC12949644